Italia markets open in 8 hours 44 minutes

InflaRx N.V. (IFRX)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,4400-0,0400 (-2,70%)
Alla chiusura: 04:00PM EDT
1,4200 -0,02 (-1,39%)
Dopo ore: 05:22PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,4800
Aperto1,4900
Denaro0,0000 x 0
Domanda0,0000 x 0
Min-Max giorno1,4300 - 1,5100
Intervallo di 52 settimane1,1400 - 4,7000
Volume209.759
Media Volume213.017
Capitalizzazione84,792M
Beta (mensile su 5 anni)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-0,7600
Prossima data utili08 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A8,02
  • GlobeNewswire

    InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

    MAA for vilobelimab was submitted in JulyMAA has been validated by EMA and is now under reviewRegulatory submission based on pivotal data from PANAMO Phase III trialCompany announces attendance at upcoming scientific and investor events JENA, Germany, Aug. 30, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that the Company has submitted a Marketing Authorization Application (

  • GlobeNewswire

    InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

    • Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending dose (MAD) Phase I trial • Progress in clinical development of vilobelimab in other indications, including cutaneous squamous cell carcinoma (cSCC) and pyoderma gangrenosum (PG) • Strong addition to management team as Camilla Chong, M.D., joins as Chief Medical Officer • Ca

  • GlobeNewswire

    InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

    Camilla Chong, M.D., joins the team with 25 years of experience in the global pharmaceutical industry in drug developmentDr. Chong to lead clinical development of InflaRx’s portfolio of C5a/C5aR inhibitors JENA, Germany, June 28, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company commercializing and developing anti-inflammatory therapeutics that target the complement system, today announced the appointment of Dr. Camilla Chong as Chief Medical Office